ARTICLE
16 June 2025

研发加IP,医药公司发展壮大的好方法

CP
CCPIT Patent & Trademark Law Office

Contributor

CCPIT PATENT AND TRADEMARK LAW OFFICE is the oldest and one of the largest full-service intellectual property law firms in China. Our firm has 322 patent and trademark attorneys, among whom 93 are qualified as attorneys-at-law. We provide consultation, prosecution, mediation, administrative enforcement and litigation services relating to patents, trademarks, copyrights, domain names, trade secrets, trade dress, unfair competition and other intellectual property-related matters. headquartered in Beijing, we have branch offices in New York, Silicon Valley, Tokyo, Munich, Madrid, Hongkong, Shanghai,Guangzhou and Shenzhen.
4月30日,百济神州公告表示,美国专利商标局(USPTO)近日作出决定,宣告Pharmacyclics公司持有的第11672803号美国专利(以下简称"803专利")全部权利要求无效。
China Intellectual Property

说及IP,也就是知识产权,要说最近可谓最大的与医药、与IP均相关的消息可能有两个,都与百济神州相关:

4月30日,百济神州公告表示,美国专利商标局(USPTO)近日作出决定,宣告Pharmacyclics公司持有的第11672803号美国专利(以下简称"803专利")全部权利要求无效。

百济神州有限公司(纳斯达克代码:ONC;香港联交所代码:06160;上交所代码:688235)是一家全球肿瘤治疗创新公司,宣布新英文名称BeOne Medicines Ltd.,的启用以及注册地从开曼迁至瑞士的事项已正式生效,达成公司发展进程中的又一重要里程碑。
百济神州联合创始人、董事长兼首席执行官欧雷强先生表示,"百悦泽®作为公司血液肿瘤治疗的基石产品,取得了爆炸式增长;......新篇章伊始,我期待与大家一起以BeOne之名,携手共赴未来。"

1637662.jpg

1637662a.jpg

两条消息的"主人公"都是百济神州公司,既然如此,我们就从相对熟悉的裁定开始分析吧。

请点击此处阅读文章正文。

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More